Before Indian drugmaker Aurobindo can complete its acquisition of Pennsylvania generics specialist Lannet, it will have to ...

After disclosing a security breach last week concerning “a limited number of internal IT systems,” details on the cyber ...

Four years after Spero Therapeutics received a complete response letter from the FDA, rejecting its oral treatment for ...

With pharma and life sciences deal values surpassing $65 billion in Q1, marking the strongest quarter in the industry since ...

With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line ...

As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business.  | ...

While describing the new import approval as a “tremendous step toward making prescription drugs affordable for all Coloradans ...

In another Novo Nordisk manufacturing update, the company announced locally that it will invest 200 million yuan ($29 million ...

Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...

With an increasingly promising roster of approved cell therapies still burdened by complex manufacturing, multiple companies ...

Recipharm has sketched out a “multi-million-dollar” investment in its U.S. manufacturing operations as part of a move to ...

TV spot for Exdensur, stepping up promotion of an asthma drug that th | GSK has launched the first direct-to-consumer TV spot ...